Visual Abstract

Introduction: Overall survival of patients with end-stage renal disease (ESRD) remains poor. Oxidative stress is one of the major risk factors associated with mortality in this patient group. As glutathione S-transferases (GST) are well-established antioxidants, we hypothesized that a model including GST gene polymorphisms, oxidative damage byproducts and cell adhesion markers has a prognostic role in ESRD patient survival. Methods: A prospective study of 199 patients with ESRD on haemodialysis was conducted. GST genotype, oxidative stress byproducts and cell adhesion molecules were measured in plasma. Multivariate Cox regression and Kaplan-Meier survival analyses were performed to test the predictive ability of these parameters in the 8-year follow-up period. Results: GSTM1-null genotype was associated with significantly shorter overall (HR 1.6, p = 0.018) and cardiovascular-specific (HR 2.1, p = 0.010) survival. Oxidative stress byproducts (advanced oxidation protein products [AOPP], prooxidant-antioxidant balance [PAB], malondialdehyde [MDA]) and cell adhesion molecules (soluble vascular cell adhesion molecule-1 [sVCAM-1] and soluble intercellular adhesion molecule-1 [sICAM-1]) demonstrated a significant predictive role in terms of overall and cardiovascular survival. When 6 biomarkers (GSTM1 genotype, high AOPP/PAB/MDA/-sVCAM-1/sICAM-1) were combined into a scoring model, a significantly shorter overall and cardiovascular survival was observed for patients with the highest score (p < 0.001). Conclusion: We identified a novel panel of biomarkers that can be utilized in predicting survival in ESRD patients. This biomarker signature could enable better monitoring of patients and stratification into appropriate treatment groups.

Go AS. Cardiovascular Disease Consequences of CKD.
Semin Nephrol
. 2016 Jul;36(4):293–304.
Himmelfarb J. Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg?
Semin Dial
. 2004 Nov-Dec;17(6):449–54.
Errakonda PR, Paladugu R, Bitla AR, Musturu SM, Lakshman J, Pemmaraju SR, et al. Effect of a single hemodialysis session on endothelial dysfunction.
J Nephrol
. 2011 Jan-Feb;24(1):83–90.
Wratten ML, Galaris D, Tetta C, Sevanian A. Evolution of oxidative stress and inflammation during hemodialysis and their contribution to cardiovascular disease.
Antioxid Redox Signal
. 2002 Dec;4(6):935–44.
Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients.
Nephrol Dial Transplant
. 2018 Oct;33(suppl_3):iii28–34.
dell’Oglio MP, Simone S, Ciccone M, Corciulo R, Gesualdo M, Zito A, et al. Neutrophil-dependent pentraxin-3 and reactive oxygen species production modulate endothelial dysfunction in haemodialysis patients.
Nephrol Dial Transplant
. 2017 Sep;32(9):1540–9.
Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis.
Arterioscler Thromb Vasc Biol
. 2004 Jul;24(7):1309–14.
Suvakov S, Damjanovic T, Stefanovic A, Pekmezovic T, Savic-Radojevic A, Pljesa-Ercegovac M, et al. Glutathione S-transferase A1, M1, P1 and T1 null or low-activity genotypes are associated with enhanced oxidative damage among haemodialysis patients. Nephrol Dial Transplant. 2013 Jan;28(1):202–12.
Suvakov S, Damjanovic T, Pekmezovic T, Jakovljevic J, Savic-Radojevic A, Pljesa-Ercegovac M, et al. Associations of GSTM1*0 and GSTA1*A genotypes with the risk of cardiovascular death among hemodialyses patients. BMC Nephrol. 2014 Jan;15(1):12.
Linhartova K, Sterbakova G, Racek J, Cerbak R, Porazikova K, Rokyta R. Linking soluble vascular adhesion molecule-1 level to calcific aortic stenosis in patients with coronary artery disease.
Exp Clin Cardiol
. 2009;14(3):e80–3.
Radecke CE, Warrick AE, Singh GD, Rogers JH, Simon SI, Armstrong EJ. Coronary artery endothelial cells and microparticles increase expression of VCAM-1 in myocardial infarction.
Thromb Haemost
. 2015 Mar;113(3):605–16.
Jocelyn PC. Spectrophotometric assay of thiols.
Methods Enzymol
. 1987;143:44–67.
Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia.
Kidney Int
. 1996 May;49(5):1304–13.
Dousset JC, Trouilh M, Foglietti MJ. Plasma malonaldehyde levels during myocardial infarction.
Clin Chim Acta
. 1983 Apr;129(3):319–22.
Erel O. A new automated colorimetric method for measuring total oxidant status.
Clin Biochem
. 2005 Dec;38(12):1103–11.
Alamdari DH, Paletas K, Pegiou T, Sarigianni M, Befani C, Koliakos G. A novel assay for the evaluation of the prooxidant-antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin Biochem. 2007 Feb;40(3-4):248–54.
Datta SK, Kumar V, Pathak R, Tripathi AK, Ahmed RS, Kalra OP, et al. Association of glutathione S-transferase M1 and T1 gene polymorphism with oxidative stress in diabetic and nondiabetic chronic kidney disease.
Ren Fail
. 2010;32(10):1189–95.
Tiwari AK, Prasad P, B K T, Kumar KM, Ammini AC, Gupta A, et al. Oxidative stress pathway genes and chronic renal insufficiency in Asian Indians with Type 2 diabetes.
J Diabetes Complications
. 2009 Mar-Apr;23(2):102–11.
Lin YS, Hung SC, Wei YH, Tarng DC. GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients.
J Am Soc Nephrol
. 2009 Feb;20(2):405–15.
Himmelfarb J, Hakim RM. Oxidative stress in uremia.
Curr Opin Nephrol Hypertens
. 2003 Nov;12(6):593–8.
Bogaards JJ, Venekamp JC, Salmon FG, van Bladeren PJ. Conjugation of isoprene monoepoxides with glutathione, catalyzed by alpha, mu, pi and theta-class glutathione S-transferases of rat and man.
Chem Biol Interact
. 1999 Jan;117(1):1–14.
Singhal SS, Zimniak P, Awasthi S, Piper JT, He NG, Teng JI, et al. Several closely related glutathione S-transferase isozymes catalyzing conjugation of 4-hydroxynonenal are differentially expressed in human tissues.
Arch Biochem Biophys
. 1994 Jun;311(2):242–50.
Yang Y, Parsons KK, Chi L, Malakauskas SM, Le TH. Glutathione S-transferase-micro1 regulates vascular smooth muscle cell proliferation, migration, and oxidative stress.
. 2009 Dec;54(6):1360–8.
Cora T, Tokac M, Acar H, Soylu A, Inan Z. Glutathione S-transferase M1 and T1 genotypes and myocardial infarction.
Mol Biol Rep
. 2013 Apr;40(4):3263–7.
Agrawal S, Tripathi G, Khan F, Sharma R, Baburaj VP. Relationship between GSTs gene polymorphism and susceptibility to end stage renal disease among North Indians.
Ren Fail
. 2007;29(8):947–53.
Lentini P, de Cal M, Cruz D, Chronopoulos A, Soni S, Nalesso F, et al. The role of advanced oxidation protein products in intensive care unit patients with acute kidney injury.
J Crit Care
. 2010 Dec;25(4):605–9.
Guo ZJ, Niu HX, Hou FF, Zhang L, Fu N, Nagai R, et al. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway.
Antioxid Redox Signal
. 2008 Oct;10(10):1699–712.
Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease.
. 2002 May;162(1):221–5.
Gonzalez E, Bajo MA, Carrero JJ, Lindholm B, Grande C, Sánchez-Villanueva R, et al. An Increase of Plasma Advanced Oxidation Protein Products Levels Is Associated with Cardiovascular Risk in Incident Peritoneal Dialysis Patients: A Pilot Study.
Oxid Med Cell Longev
. 2015;2015:219569.
Kocak H, Gumuslu S, Sahin E, Ceken K, Gocmen YA, Yakupoglu G, et al. Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients.
Nephrology (Carlton)
. 2009 Apr;14(3):273–80.
Wei XF, Zhou QG, Hou FF, Liu BY, Liang M. Advanced oxidation protein products induce mesangial cell perturbation through PKC-dependent activation of NADPH oxidase.
Am J Physiol Renal Physiol
. 2009 Feb;296(2):F427–37.
Zhou LL, Hou FF, Wang GB, Yang F, Xie D, Wang YP, et al. Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms.
Kidney Int
. 2009 Dec;76(11):1148–60.
Ghayour-Mobarhan M, Alamdari DH, Moohebati M, Sahebkar A, Nematy M, Safarian M, et al. Determination of prooxidant–antioxidant balance after acute coronary syndrome using a rapid assay: a pilot study.
. 2009 Dec;60(6):657–62.
Hennig B, Chow CK. Lipid peroxidation and endothelial cell injury: implications in atherosclerosis.
Free Radic Biol Med
. 1988;4(2):99–106.
Dong J, Li YJ, Yang ZK, Xu R. Prognostic value of serum von Willebrand factor, but not soluble ICAM and VCAM, for mortality and cardiovascular events is independent of residual renal function in peritoneal dialysis patients.
Perit Dial Int
. 2014 Nov-Dec;34(7):706–13.
Papagianni A, Kalovoulos M, Kirmizis D, Vainas A, Belechri AM, Alexopoulos E, et al. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients.
Nephrol Dial Transplant
. 2003 Jan;18(1):113–9.
De Caterina R, Basta G, Lazzerini G, Dell’Omo G, Petrucci R, Morale M, et al. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis.
Arterioscler Thromb Vasc Biol
. 1997 Nov;17(11):2646–54.
Papagianni A, Dovas S, Bantis C, Belechri AM, Kalovoulos M, Dimitriadis C, et al. Carotid atherosclerosis and endothelial cell adhesion molecules as predictors of long-term outcome in chronic hemodialysis patients.
Am J Nephrol
. 2008;28(2):265–74.
Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling.
J Am Soc Nephrol
. 2005 Mar;16(suppl 1):S83–8.
Sakuma N, Hibino T, Sato T, Ohte N, Akita S, Tamai N, et al. Levels of thiobarbituric acid-reactive substance in plasma from coronary artery disease patients.
Clin Biochem
. 1997 Aug;30(6):505–7.
Walter MF, Jacob RF, Jeffers B, Ghadanfar MM, Preston GM, Buch J, et al.; PREVENT study. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study.
J Am Coll Cardiol
. 2004 Nov;44(10):1996–2002.
Terrier-Lenglet A, Nollet A, Liabeuf S, Barreto DV, Brazier M, Lemke HD, et al.; Groupe EUTox (European Uremic toxin). [Plasma malondialdehyde may not predict mortality in patient with chronic kidney disease]. Nephrol Ther. 2011 Jul;7(4):219–24.
Kotani K, Tashiro J, Yamazaki K, Nakamura Y, Miyazaki A, Bujo H, et al. Investigation of MDA-LDL (malondialdehyde-modified low-density lipoprotein) as a prognostic marker for coronary artery disease in patients with type 2 diabetes mellitus.
Clin Chim Acta
. 2015 Oct;450:145–50.
Fleischmann EH, Bower JD, Salahudeen AK. Are conventional cardiovascular risk factors predictive of two-year mortality in hemodialysis patients?
Clin Nephrol
. 2001 Sep;56(3):221–30.
Bayés B, Pastor MC, Bonal J, Foraster A, Romero R. Oxidative stress, inflammation and cardiovascular mortality in haemodialysis—role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up.
Nephrol Dial Transplant
. 2006 Apr;21(4):984–90.
Wang Z, Yu C, Li XH, Deng BQ. The prognostic value of oxidative stress and inflammation in Chinese hemodialysis patients.
Ren Fail
. 2017 Nov;39(1):54–8.
Chang JF, Hsu SP, Pai MF, Yang JY, Chen HY, Wu HY, et al. High soluble vascular cell adhesion molecule-1 concentrations predict long-term mortality in hemodialysis patients.
Int Urol Nephrol
. 2013 Dec;45(6):1693–701.
Miskulin D, Bragg-Gresham J, Gillespie BW, Tentori F, Pisoni RL, Tighiouart H, et al. Key comorbid conditions that are predictive of survival among hemodialysis patients. Clin J Am Soc Nephrol. 2009 Nov;4(11):1818–26.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.